OnKure Therapeutics Inc (OKUR): Analyst Consensus Forecast

Symbol and logo of brand OnKure (OKUR)

OnKure Therapeutics Inc (OKUR) is developing high-precision tumor therapies, aiming for patent leadership and the establishment of premium pricing for its developments. This price trend chart, with a current reading of 13.30, reflects the asset's dynamics. The business relies on R&D processes that are independent of market cycles and operates within a stable US legal framework, remaining fully insulated from international political conflicts.

Price Target Chart: OnKure Therapeutics, Inc. (OKUR) for 10/08/2024 - 11/15/2026

Analytical breakdowns for onkuretherapeutics.com (OKUR)

- current quotes and average value forecast:
Fundamental company analysis:OnKure (OKUR)
Original product of OnKure Therapeutics Inc

To minimize capital risks, investors compare the current asset value with its fair potential. In the case of OnKure Therapeutics Inc (OKUR), success depends on the commercialization of PI3Kalpha inhibitors; therefore, the market consensus forecast reflects the gap between the market price and the average expectations of oncotherapy experts, where an upward curve signals a revaluation of the business's fundamental value relative to industry standards.

Competing companies

ONC - Average Forecast Price|Analyst Consensus Forecast HALO (Halozyme Therapeutics, Inc.)|Revolution Medicines Corp - Price Target Chart|AAPG - Price Target Chart|Average Forecast Price cgoncology.com|UroGen (URGN) - Price Target Chart|Broker Consensus Forecast BCAX|PSNL (Personalis Genomics) - Analyst Consensus Forecast|Consensus Target Erasca Corp (ERAS)|Analyst Consensus Forecast DCTH|Analyst Consensus Forecast ymabs.com (YMAB)|Price Target Chart Aura Bio AURA|CADL: Broker Consensus Forecast|Accuray, Inc. - Analyst Consensus Forecast|Average Forecast Price SELLAS Life Sciences Group|ACTU: Analyst Consensus Forecast|Average Forecast Price citiusonc.com (CTOR)|Price Target Chart tuhurabio.com|TARA: Fair Value Consensus|Consensus Target FATE (Fate Therapeutics Corp)|WHWK (Aadi Bioscience) - Fair Value Consensus|Analyst Consensus Forecast TCRX (TScan Therapeutics)|CSBR - Consensus Target|XBIT: Consensus Target|Fair Value Consensus CVM (cel-sci.com)|OS Therapies Inc (OSTX) - Price Target Chart|Radiopharm Theranostics - Fair Value Consensus|ARTV (Artiva Biotherapeutics Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast Adlai Nortye Ltd.|Consensus Target VERU (Veru)|Analyst Forecast Prices TPST|Price Target Chart Xilio XLO|Renovaro Inc. (RENB) - Average Forecast Price|MURA - Price Target Chart|Analyst Median Target Kairos Pharma KAPA|w2.cytomed.sg (GDTC) - Price Target Chart|CRIS - Analyst Median Target|Price Target Chart Apollomics, Inc.|Tharimmune Corporation (THAR) - Analyst Median Target|Analyst Consensus Forecast ADVB|GNPX - Average Forecast Price|Calidi Biotherapeutics - Consensus Target|SBFM: Broker Consensus Forecast|XBIO: Consensus Target|Analyst Median Target Salarius Pharmaceuticals SLRX|PPBT: Analyst Consensus Forecast|AON - Fair Value Consensus|Consensus Target BGNE|CKPT (Checkpoint Therapeutics, Inc) - Analyst Forecast Prices|Price Target Chart Elevation Oncology Inc. (ELEV)|Consensus Target iCAD ICAD|Price Target Chart Ikena Oncology IKNA|Analyst Median Target Notable Labs (NTBL)|Viracta Therapeutics - Analyst Consensus Forecast|Average Forecast Price MorphoSys Inc|NAYA: Analyst Consensus Forecast|Ascentage (AAPGV) - Analyst Consensus Forecast